Emerging tyrosine kinase inhibitors for the treatment of adult acute lymphoblastic leukemia
Authors:
- 3 July 2021
- journal article
- other
- Published by Taylor & Francis in Expert Opinion on Emerging Drugs
- Vol. 26 (3) , 281-294
Abstract
Introduction: The broadening of targeted and immunotherapeutic strategies markedly impacted on the management of acute lymphoblastic leukemia (ALL). The advent of tyrosine kinase inhibitors (TKIs) changed the history of Philadelphia-chromosome positive (Ph+) ALL. Nowadays, almost all Ph+ ALL patients treated with TKIs achieve a complete hematologic response, and most become minimal residual disease negative. In Ph- ALL, genomic profiling studies have identified a subtype associated with a high relapse risk and a transcriptional profile similar to that of Ph+ ALL, the so-called Ph-like ALL. Given the high prevalence of kinase-activating lesions in this subset, there is compelling evidence from experimental models and clinical observations favoring TKI administration. Areas covered: We discuss the main findings exploring the efficacy of TKIs in ALL. Expert opinion: The use of more potent TKIs will further enhance the inhibitory activity on leukemia cells and increase the possibility of eradicating the disease at a molecular level. In the future, ‘combined’ approaches of different inhibitors may be considered to prevent/avoid resistance and/or mutations. A rapid identification of Ph-like ALL patients is needed to propose early TKI-based intervention. Several questions remain open, including the initial TKI choice in Ph+ ALL and whether Ph-like ALL patients might benefit from immunotherapy.Keywords
Funding Information
- Italiana per la Ricerca sul Cancro (Metastases 5 × 1000 Special Program, N° 21198)
This publication has 131 references indexed in Scilit:
- Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome—positive acute lymphoblastic leukemiaLeukemia, 2012
- Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemiaBlood, 2010
- A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification studyThe Lancet Oncology, 2009
- Deletion ofIKZF1and Prognosis in Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 2009
- Long-term remission of Philadelphia chromosome–positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation–etoposide regimenBlood, 2008
- Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemiaJournal of Experimental Medicine, 2008
- Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potencyJournal of Clinical Investigation, 2007
- Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome–positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocolBlood, 2007
- NUP214-ABL1 in adult T-ALL: the GMALL study group experienceBlood, 2006
- Myths and Lessons from the Adult/Pediatric Interface in Acute Lymphoblastic LeukemiaHematology-American Society Hematology Education Program, 2006